Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shi-Ming Tu

Showing results (81-90 of 131) with videos related to

Pageof 14
Sort By:
European Urology Oncology|August 15, 2019
Robotic Postchemotherapy Retroperitoneal Lymph Node Dissection for Testicular CancerRoger Li, Jonathan J Duplisea, Firas G Petros, et al.
Journal of Neurosurgery. Spine|May 16, 2009
Surgical management of prostate cancer metastatic to the spineBrian J Williams, Benjamin D Fox, Daniel M Sciubba, et al.
European Urology|June 3, 2014
Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancerEleni Efstathiou, Mark Titus, Sijin Wen, et al.
Cancer|January 28, 2003
Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinomaDanai D Daliani, Vasily Assikis, Shi-Ming Tu, et al.
The Journal of Urology|March 27, 2007
Surgical management of growing teratoma syndrome: the M. D. Anderson cancer center experiencePhilippe E Spiess, Wassim Kassouf, Gordon A Brown, et al.
The Journal of Urology|December 13, 2006
Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissectionPhilippe E Spiess, Gordon A Brown, Ping Liu, et al.
Urologic Oncology|December 13, 2003
Treatment of refractory urothelial carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, alpha-interferon, cisplatin (FAP)Shi-Ming Tu, Randall E Millikan, Lance C Pagliaro, et al.
Cancer|September 1, 2006
Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters?Philippe E Spiess, Gordon A Brown, Louis L Pisters, et al.
Cancer|September 1, 2006
Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancerPhilippe E Spiess, Gordon A Brown, Ping Liu, et al.
Cancers|December 9, 2023
Stem Cell Theory of Cancer: Clinical Implications of Epigenomic versus Genomic Biomarkers in Cancer CareShi-Ming Tu, Jim Zhongning Chen, Sunny R Singh, et al.
Pageof 14

Showing results (81-90 of 131) with videos related to

Sort By:
Pageof 14
European Urology Oncology|August 15, 2019
Robotic Postchemotherapy Retroperitoneal Lymph Node Dissection for Testicular CancerRoger Li, Jonathan J Duplisea, Firas G Petros, et al.
Journal of Neurosurgery. Spine|May 16, 2009
Surgical management of prostate cancer metastatic to the spineBrian J Williams, Benjamin D Fox, Daniel M Sciubba, et al.
European Urology|June 3, 2014
Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancerEleni Efstathiou, Mark Titus, Sijin Wen, et al.
Cancer|January 28, 2003
Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinomaDanai D Daliani, Vasily Assikis, Shi-Ming Tu, et al.
The Journal of Urology|March 27, 2007
Surgical management of growing teratoma syndrome: the M. D. Anderson cancer center experiencePhilippe E Spiess, Wassim Kassouf, Gordon A Brown, et al.
The Journal of Urology|December 13, 2006
Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissectionPhilippe E Spiess, Gordon A Brown, Ping Liu, et al.
Urologic Oncology|December 13, 2003
Treatment of refractory urothelial carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, alpha-interferon, cisplatin (FAP)Shi-Ming Tu, Randall E Millikan, Lance C Pagliaro, et al.
Cancer|September 1, 2006
Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters?Philippe E Spiess, Gordon A Brown, Louis L Pisters, et al.
Cancer|September 1, 2006
Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancerPhilippe E Spiess, Gordon A Brown, Ping Liu, et al.
Cancers|December 9, 2023
Stem Cell Theory of Cancer: Clinical Implications of Epigenomic versus Genomic Biomarkers in Cancer CareShi-Ming Tu, Jim Zhongning Chen, Sunny R Singh, et al.
Pageof 14